APYX · Apyx Medical Corp - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $12.49M | - | $12.88M | $11.37M | $9.43M | - | $11.49M | $12.15M | $10.24M | - |
| Cost of Revenue | $4.57M | - | $4.58M | $4.29M | $3.77M | - | $4.53M | $4.66M | $4.29M | - |
| Gross Profit | $7.92M | - | $8.30M | $7.08M | $5.67M | - | $6.95M | $7.49M | $5.95M | - |
| R&D | $765.0K | - | $801.0K | $824.0K | $804.0K | - | $1.14M | $1.42M | $1.40M | - |
| SG&A | $3.58M | - | $3.66M | $4.14M | $3.38M | - | $4.29M | $4.84M | $4.90M | - |
| Total Operating Expenses | $8.84M | - | $9.13M | $9.66M | $8.72M | - | $10.59M | $13.04M | $12.56M | - |
| D&A | $202.0K | - | - | - | $138.0K | - | - | - | $157.0K | - |
| Operating Income | ($911.0K) | - | ($832.0K) | ($2.57M) | ($3.05M) | - | ($3.63M) | ($5.55M) | ($6.62M) | - |
| Interest Expense | $1.37M | - | $1.41M | $1.43M | $1.40M | - | $1.43M | $1.43M | $1.40M | - |
| Income Tax | $143.0K | - | $78.0K | $49.0K | $49.0K | - | $60.0K | $50.0K | $53.0K | - |
| Net Income | ($2.11M) | - | ($1.98M) | ($3.78M) | ($4.15M) | - | ($4.70M) | ($6.56M) | ($7.58M) | - |
| EPS - Basic | ($0.05) | - | ($0.05) | ($0.09) | ($0.10) | - | ($0.14) | ($0.19) | ($0.22) | - |
| EPS - Diluted | - | - | - | - | - | - | - | ($0.19) | ($0.22) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $31.14M | $31.74M | $25.14M | $29.30M | $31.01M | $31.74M | $28.01M | $32.68M | $37.28M | $43.65M |
| Accounts Receivable | $12.76M | $16.78M | $12.99M | $11.25M | $11.64M | $15.48M | $13.04M | $12.71M | $12.49M | $14.02M |
| Inventory | $9.54M | $8.60M | $9.14M | $8.19M | $7.68M | $7.56M | $9.00M | $9.32M | $9.79M | $9.92M |
| Accounts Payable | $2.63M | $3.06M | $3.22M | $2.89M | $2.31M | $2.62M | $1.91M | $2.35M | $2.10M | $2.71M |
| Current Assets | $54.80M | $58.47M | $48.79M | $49.91M | $51.85M | $56.44M | $52.16M | $56.67M | $61.93M | $70.36M |
| Total Assets | $63.02M | $66.84M | $57.37M | $58.19M | $60.16M | $64.84M | $60.72M | $65.39M | $70.71M | $79.24M |
| Current Liabilities | $9.45M | $11.70M | $10.98M | $10.57M | $9.51M | $10.72M | $9.55M | $10.64M | $10.56M | $12.74M |
| Long-term Debt | $35.09M | $34.85M | $34.61M | $34.37M | $34.13M | $33.89M | $33.85M | $33.63M | $33.41M | $33.19M |
| Total Liabilities | $49.94M | $52.01M | $51.28M | $50.73M | $49.52M | $50.51M | $49.52M | $50.47M | $50.25M | $52.32M |
| Stockholders' Equity | $12.83M | $14.54M | $5.85M | $7.25M | $10.51M | $14.21M | $11.04M | $14.75M | $20.25M | $26.70M |
| Retained Earnings | ($91.23M) | ($89.12M) | ($87.82M) | ($85.84M) | ($82.06M) | ($77.91M) | ($73.28M) | ($68.58M) | ($62.02M) | ($54.45M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($572.0K) | - | - | - | ($702.0K) | - | - | - | ($6.34M) | - |
| Investing Cash Flow | ($60.0K) | - | - | - | ($55.0K) | - | - | - | ($35.0K) | - |
| Financing Cash Flow | $83.0K | - | - | - | $25.0K | - | - | - | ($5.0K) | - |
| CapEx | $60.0K | - | - | - | $55.0K | - | - | - | $35.0K | - |
| Free Cash Flow | ($632.0K) | - | - | - | ($757.0K) | - | - | - | ($6.38M) | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | 63.5% | - | 64.4% | 62.3% | 60.1% | - | 60.5% | 61.7% | 58.1% | - |
| Operating margin | -7.3% | - | -6.5% | -22.6% | -32.4% | - | -31.6% | -45.7% | -64.6% | - |
| EBITDA margin | -5.7% | - | - | - | -30.9% | - | - | - | -63.0% | - |
| Net margin | -16.9% | - | -15.4% | -33.2% | -44.0% | - | -40.9% | -54.0% | -74.0% | - |
| Free cash flow margin | -5.1% | - | - | - | -8.0% | - | - | - | -62.2% | - |
| FCF / Net income | 0.30 | - | - | - | 0.18 | - | - | - | 0.84 | - |
| R&D / Revenue | 6.1% | - | 6.2% | 7.2% | 8.5% | - | 9.9% | 11.7% | 13.6% | - |
| SG&A / Revenue | 28.6% | - | 28.4% | 36.4% | 35.9% | - | 37.4% | 39.8% | 47.8% | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -3.3% | - | -3.5% | -6.5% | -6.9% | - | -7.7% | -10.0% | -10.7% | - |
| Return on equity | -16.4% | - | -33.9% | -52.1% | -39.5% | - | -42.6% | -44.5% | -37.4% | - |
| Return on invested capital | -1.5% | - | -1.6% | -4.9% | -5.4% | - | -6.4% | -9.1% | -9.7% | - |
| Liquidity | ||||||||||
| Current ratio | 5.80 | 5.00 | 4.44 | 4.72 | 5.45 | 5.26 | 5.46 | 5.33 | 5.87 | 5.52 |
| Quick ratio | 4.79 | 4.26 | 3.61 | 3.95 | 4.64 | 4.56 | 4.52 | 4.45 | 4.94 | 4.74 |
| Cash ratio | 3.30 | 2.71 | 2.29 | 2.77 | 3.26 | 2.96 | 2.93 | 3.07 | 3.53 | 3.43 |
| Leverage | ||||||||||
| Debt / Equity | 2.73 | 2.40 | 5.92 | 4.74 | 3.25 | 2.39 | 3.07 | 2.28 | 1.65 | 1.24 |
| Debt / Assets | 0.56 | 0.52 | 0.60 | 0.59 | 0.57 | 0.52 | 0.56 | 0.51 | 0.47 | 0.42 |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | -0.7x | - | -0.6x | -1.8x | -2.2x | - | -2.5x | -3.9x | -4.7x | - |
| Equity multiplier | 4.91 | 4.60 | 9.81 | 8.02 | 5.72 | 4.56 | 5.50 | 4.43 | 3.49 | 2.97 |
| Liabilities / Assets | 0.79 | 0.78 | 0.89 | 0.87 | 0.82 | 0.78 | 0.82 | 0.77 | 0.71 | 0.66 |
| Efficiency | ||||||||||
| Asset turnover | 0.20 | - | 0.22 | 0.20 | 0.16 | - | 0.19 | 0.19 | 0.14 | - |
| Inventory turnover | 0.48 | - | 0.50 | 0.52 | 0.49 | - | 0.50 | 0.50 | 0.44 | - |
| Days sales outstanding | 373d | - | 368d | 361d | 451d | - | 414d | 382d | 445d | - |
| Days inventory outstanding | 762d | - | 729d | 697d | 745d | - | 725d | 731d | 832d | - |
| Days payable outstanding | 210d | - | 257d | 246d | 223d | - | 154d | 184d | 179d | - |
| Cash conversion cycle | 925d | - | 841d | 812d | 972d | - | 985d | 929d | 1099d | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | 3.1x | 2.3x | - |
| P / S | - | - | - | - | - | - | - | 3.8x | 4.6x | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | 32.4% | - | 12.1% | -6.4% | -7.9% | - | -4.1% | -10.5% | -15.6% | - |
| Revenue CAGR (3y) | 0.9% | - | 12.2% | 3.4% | -8.9% | - | -1.0% | 2.7% | 5.8% | - |
| Revenue CAGR (5y) | 7.7% | - | 13.1% | 21.5% | 13.5% | - | 25.6% | 26.9% | 12.0% | - |
| Gross profit growth (YoY) | 39.9% | - | 19.3% | -5.5% | -4.8% | - | -12.8% | -19.2% | -21.4% | - |
| Operating income growth (YoY) | 70.1% | - | 77.1% | 53.6% | 53.9% | - | 21.6% | -349.1% | -17.9% | - |
| Net income growth (YoY) | 49.2% | - | 57.8% | 42.4% | 45.2% | - | -1.6% | -559.6% | -117.5% | - |
| EPS growth (YoY) | - | - | - | - | - | - | - | -533.3% | -120.0% | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | 16.5% | - | - | - | 88.1% | - | - | - | -220.2% | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | 22.1% | 2.3% | -47.0% | -50.8% | -48.1% | -46.8% | -66.9% | -59.7% | -43.8% | -29.0% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Business segments
$52.84M totalSurgical Aesthetics$45.33M · 85.8%
Oem$7.51M · 14.2%
Geographic
$52.84M totalUS$38.80M · 73.4%
Non Us$14.04M · 26.6%
Peer comparison
Same SIC group: Surgical & Medical Instruments & Apparatus
Comparing Apyx Medical Corp against the 5 most active filers in the same SIC group.